Background: Prevalence of Alzheimer’s disease in people with Down’s syndrome is very high, and many such individuals who are older than 40 years have pathological changes characteristic of Alzheimer’s disease. Evidence to support treatment with Alzheimer’s drugs is inadequate, although memantine is beneficial in transgenic mice. We aimed to assess safety and efficacy of memantine […]